Author:
Narang Kushal,Kadian Mohit,Venkatesan K,Mishra Saumyaranjan,Bisht Shyam,Gupta Deepak,Banerjee Susovan,Kataria Tejinder
Reference30 articles.
1. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial;Dearnaley DP;Lancet Oncol,2014
2. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial;Dearnaley DP;Lancet Oncol,2016
3. Hyprofractionated versus conventionally fractionated radiation therapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-year outcomes from the randomized, multicenter, open-label, phase 3 HYPRO trial;de Vries KC;Int J Radiat Oncol Biol Phys,2020
4. Patient reported outcomes in NRG Oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer;Lukka HR;Int J Radiat Oncol Biol Phys,2018
5. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study;Miralbell R;Int J Radiat Oncol Biol Phys,2010
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. PSMA‐PET‐guided dose‐escalated volumetric arc therapy for newly diagnosed lymph node‐positive prostate cancer: 5 Year outcomes following the FROGG and EviQ node‐positive guidelines;Journal of Medical Imaging and Radiation Oncology;2023-04-26
2. Virtual HDR Boost for Prostate Cancer: Rebooting a Classic Treatment Using Modern Tech;Cancers;2023-03-28
3. Re: Kumar A, Yadav S, Krishnappa RS, Gautam G, Raghavan N, Bakshi G, et al. The Urological Society of India guidelines for the evaluation and management of prostate cancer (executive summary). Indian J Urol 2022;38:252-7;Indian Journal of Urology;2023
4. Author reply Re:Kumar A, Yadav S, Krishnappa RS, Gautam G, Raghavan N, Bakshi G, et al. The Urological Society of India guidelines for the evaluation and management of prostate cancer (executive summary). Indian J Urol 2022;38:252-257;Indian Journal of Urology;2023
5. Short-Term Outcomes and Clinical Efficacy of Stereotactic Body Radiation Therapy (SBRT) for Oligometastases of Prostate Cancer in China;Frontiers in Oncology;2022-04-28